About: Hydroxychloroquine and tocilizumab therapy in COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
Creator	Rose, Keith Sperber, Steven Balani, Bindu Berry, Scott Asif, Arif Bednarz, Urszula Barsky, Carol Berry, Donald Berry, Nicholas Biran, Noa Cicogna, Cristina Goy, Andre Hansen, Eric Jacobs, Laurie Korcak, Jason Landolfi, Joseph Marafelias, Michael Mathura, Shivam Pecora, Andrew Piwoz, Julia Sawczuk, Ihor Sebti, Rani Sinclaire, Brittany Sugalski, Gregory Tank, Lisa Timmapuri, Sarah Underwood, Joseph Varga, Daniel Zuckerman, Jerry Goid, Ronaldo Goldbergid, Stuart Ipid, Andrew
Source	Medline; PMC
abstract	Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients. In this retrospective observational cohort study drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients were hospitalized at a 13-hospital network spanning New Jersey USA between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80–1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83–1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75–1.28]). The 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively. Among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57–1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients. Tocilizumab demonstrated a trend association towards reduced mortality among ICU patients. Our findings are limited to hospitalized patients and must be interpreted with caution while awaiting results of randomized trials. Trial Registration: Clinicaltrials.gov Identifier: NCT04347993
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0237693
bibo:pmid	32790733
has license	cc-by
sha1sum (hex)	380c7b17a8fd794e086b731e81531a5043569993
schema:url	https://doi.org/10.1371/journal.pone.0237693
resource representing a document's title	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
has PubMed Central identifier	PMC7425928
has PubMed identifier	32790733
schema:publication	PLoS One
resource representing a document's body	covid:380c7b17a8fd794e086b731e81531a5043569993#body_text
is schema:about of	named entity 'COMPARED' named entity 'APRIL' named entity 'ASSOCIATED' named entity 'HOSPITALIZED' named entity 'FINDINGS' named entity 'ICU' named entity 'Tocilizumab' named entity 'cohort study' named entity '95% CI' named entity 'hydroxychloroquine' named entity 'tocilizumab' named entity 'ICU' named entity 'hydroxychloroquine' named entity 'COVID' named entity 'azithromycin' named entity 'hydroxychloroquine' named entity 'Tocilizumab' named entity 'hydroxychloroquine' named entity 'tocilizumab' named entity 'Hydroxychloroquine' named entity 'observational study' named entity 'March 28' named entity 'infection' named entity 'tocilizumab' named entity 'COPD' named entity 'Protected health information' named entity 'tocilizumab' named entity 'Propensity scores' named entity 'arrhythmia' named entity 'control population' named entity 'tocilizumab' named entity 'heart failure' named entity 'intubation' named entity 'ordinal scale' named entity 'COVID' named entity 'inclusion and exclusion criteria' named entity 'propensity scores' named entity 'COVID' named entity 'inflammatory bowel disease' named entity 'diabetes' named entity 'ICU' named entity 'hypertension' named entity 'chronic conditions' named entity 'tocilizumab' named entity 'hydroxychloroquine' named entity 'azithromycin' named entity 'observational study' named entity 'QTc' named entity 'hypertension' named entity '1, 2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software